CA Patent

CA2695012A1 — Treatment with kallikrein inhibitors

Assigned to Genzyme Corp · Expires 2009-02-26 · 17y expired

What this patent protects

Methods, kits and compositions are disclosed that include a non-naturally occurring kallikrein inhibitor and an optional additional gout therapeutic for the treatment of gout, such as acute gout.

USPTO Abstract

Methods, kits and compositions are disclosed that include a non-naturally occurring kallikrein inhibitor and an optional additional gout therapeutic for the treatment of gout, such as acute gout.

Drugs covered by this patent

Patent Metadata

Patent number
CA2695012A1
Jurisdiction
CA
Classification
—
Expires
2009-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.